Refractory CLL Therapeutic Development Reviewed in Global Markets Direct Study Available at MarketPublishers.com

25 Sep 2013 • by Natalie Aster

LONDON – Chronic lymphocytic leukemia (CLL), one of the chronic lymphoproliferative disorders, is characterised by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. CLL remains an incurable disease with an extremely variable course; survival after diagnosis can range from months to decades. A variety of genomic features provide further differentiation of disease prognosis. With the improvement of its associated prognostic and therapy response factors, the treatment of CLL has changed dramatically.

A lot of patients are now being treated with more effective agents such as purine analogues, either alone or combined with other drugs and/or monoclonal antibodies. Apart from monoclonal antibody therapies, a good number of small molecules are being examined for treating the disease. Most of these agents aim to overcome apoptosis resistance in CLL cells or influence the microenvironment. Up to now the most promising agents are considered to be flavopiridol and lenalidomide, among others. Some of the major companies involved in refractory CLL therapeutics development include Genta Incorporated, Celgene Corporation, Pharmacyclics, Inc., and SBI Biotech Co., Ltd.

In-demand research study “Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013” elaborated by Global Markets Direct provides an accurate and comprehensive overview of the worldwide therapeutic development for refractory chronic lymphocytic leukemia.

The report reviews the important and diverse CLL products under development by companies and different research organisations; reviews the products being in various phases of development – from discovery till registration; features pipeline projects based on monotherapy and combined therapeutics; covers the refractory CLL pipeline on the basis of molecule type and route of administration; sheds light on the discontinued projects and looks into the factors that drove them from pipeline. Additionally, the emerging players with potentially strong product portfolio are discussed, and also the most recent news and deals relating to the products are uncovered.

Report Details:

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013
Published: August, 2013
Pages: 77
Price: US$ 2,000.00

More Pipeline Reviews H2 2013 by Global Markets Direct Include:

More in-demand studies by the publisher can be found at Global Markets Direct page.

CONTACTS

The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com